Skip directly to content


Ibrance® is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer1. Ibrance® has been enlisted as subsidized medical treatment against one specific disease by the Community Care Fund2.


  1. Ibrance® (palbociclib) Prescribing Information. Pfizer Corporation Hong Kong Limited: Version (January 2018)
  2. Items Supported by the Samaritan Fund and Community Care Fund Medical Assistance Programme. Hong Kong Hospital Authority. Accessed on 6 June 2019. Available at


[PP-CPF-HKG-0070] SEP 2019

Therapeutic Area Sub Category: